Noramco
Noramco
Noramco
  • About Us
    • About Noramco
    • Our People
    • Leadership
    • Excellence in Compliance
    • Minimizing Risk
  • Products & Solutions
    • Active Pharmaceutical Ingredients
      • Active Pharmaceutical Ingredients
      • Nal Family of Antagonists
      • ADHD / Stimulants
      • Full Product List
    • Noramco Solutions
      • Noramco Solutions
      • Clinical Supply
      • Controlled Substance Building Blocks and Intermediates
    • Platform Technologies
      • Platform Technologies
      • Platform Technology: Custom Synthesis
    • Reference Standards
      • Reference Standards
      • Reference Standards: Custom Synthesis
    • Reference Standards Store
  • Careers
  • News & Events
    • News & Events
    • Press Releases
  • Contact

Sort by

  • Default sorting
  • Sort by popularity
  • Sort by newness
  • Sort by price: low to high
  • Sort by price: high to low

View

  • 9 items
  • 15 items
  • 30 items

Showing 1–9 of 20 results

  • 50_4-monobromo-Cannabidiol
    Quick ViewSelect options

    4-monobromo Cannabidiol

    $2,500.00 – $9,500.00
    <span style="color: #000000;"><strong>CAS#</strong> </span>112639-10-8
    Quick ViewSelect options
  • 37_Cannabichromene-(CBC)
    Quick ViewSelect options

    Cannabichromene (CBC)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 20675-51-8 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2180-**
    Quick ViewSelect options
  • 38_Cannabichromenic-Acid-(CBCA)
    Quick ViewSelect options

    Cannabichromenic Acid (CBCA)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 185505-15-1 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2181-**
    Quick ViewSelect options
  • 44_Cannabichromevarinic-Acid-(CBCVA)
    Quick ViewSelect options

    Cannabichromevarinic Acid (CBCVA)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 64898-02-8 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2183-**
    Quick ViewSelect options
  • 51_Cannabicyclolic-Acid-(CBLA)
    Quick ViewSelect options

    Cannabicyclolic Acid (CBLA)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 40524-99-0
    Quick ViewSelect options
  • 35_Cannabidiol-(CBD)
    Quick ViewSelect options

    Cannabidiol (CBD)

    $375.00 – $6,800.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 13956-29-1 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2155-**
    Quick ViewSelect options
  • 36_Cannabidiolic-Acid-(CBDA)
    Quick ViewSelect options

    Cannabidiolic Acid (CBDA)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 1244-58-2 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2184-**
    Quick ViewSelect options
  • 41_Cannabidivarin-(CBDV)
    Quick ViewSelect options

    Cannabidivarin (CBDV)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 24274-48-4 <span style="color: #000000;"><strong>NDC#</strong></span> 51634-2166-**
    Quick ViewSelect options
  • 45_Cannabigerol-(CBG)
    Quick ViewSelect options

    Cannabigerol (CBG)

    $3,750.00 – $13,500.00
    <span style="color: #000000;"><strong>CAS#</strong></span> 25654-31-3
    Quick ViewSelect options
  • 1
  • 2
  • 3

Recent Articles

  • Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
  • Diversifying the Supply of Raw Materials
  • Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
  • Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
  • Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide
Copyright 2025 Noramco. All Rights Reserved. Contact | Legal Notice | Privacy Policy | Terms & Conditions | Benefits Transparency Mandate